Probiodrug veröffentlicht neue Erkenntnisse zur Entstehung von Alzheimer im Journal of Neuroscience Halle/Saale, 8. September 2011 — Die Probiodrug AG, ein biopharmazeutisches Unternehmen, das sich auf […]
Publikation in EMBO Molecular Medicine erläutert kausale Rolle des Enzyms iso-Glutaminylzyklase (isoQC) Halle/Saale, 20. Juli 2011, 08:00 Uhr MESZ — Die Probiodrug AG, ein biopharmazeutisches Unternehmen, […]
Halle/Saale, March 08th 2011 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]
Halle/Saale, November 15, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]
Halle/Saale, November 12, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]
Halle/Saale, Nov. 08, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus […]
Probiodrug to Present Novel Findings on the Pathogenesis of Alzheimer’s Disease at Neuroscience 2010
Probiodrug to Present Novel Findings on the Pathogenesis of Alzheimer’s Disease at Neuroscience 2010 Halle/Saale, Nov 1st, 2010 — Probiodrug AG (Probiodrug), a biotech company developing […]
Halle/Saale, Sept.13, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on […]
Halle/Saale, July 8, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]